BeOne Medicines (ONC) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $2.05
- Estimate
- $1.63
- Surprise
- +25.7%
- Revenue (period 2026-06-30)
- $1.71B
- Score today
- 6.5/10
Revenue source: xbrl.
How the report landed
BeOne Medicines (ONC) beat the $1.63 estimate with diluted EPS of $2.05 — a large 25.7% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates ONC Buy (Wait) at 6.5/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +25.7% surprise compares with a +35.1% four-quarter average. Next scheduled report: 2026-11-05.
What supports the rating
- Strong earnings beat streak (3/4)
- High-quality business
What argues against it
- Concentration risk — Product: BRUKINSA
- Thin upside margin: 4.1%
- Near 52-week high (2.8% away)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $374.47
- Entry target
- $314.02
- Price target
- $389.71
- Stop
- $292.68
- Upside to target
- +4.1%
- Reward-to-risk
- 0.3:1
The stock trades at 67.2× trailing but 36.4× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 80 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.
ONC at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $42.36B
- P/E (fwd)
- 36.4
- P/E (ttm)
- 67.2
- 52-week range
- $253.95–$385.22
- Off 52-week high
- 2.8%
- RSI (14)
- 80
- Volume vs avg
- 0.64×
- Score today
- 6.5/10